10/19/2005 5:10:54 PM
International Wex Technologies Inc. ("Wex" or the "Company") is pleased to announce that it received regulatory approval (No Objection Letter) from Health Canada, on April 8, 2004, for initiating an Open-Label extension Clinical Trial for Tectin(TM) in patients with moderate to severe cancer-related pain. This multi-centre, safety and efficacy study is a long-term continuation of the current Pivotal Phase IIb/III trial that is underway and will be run in parallel.
In an effort to enforce Wex's commitment to improving quality of life the Company requested this study in order to make Tectin(TM) available to all patients who participate in the Pivotal Phase IIb/III trial. This will allow the patients who obtained benefit from the drug as well as those who received placebo to obtain Tectin(TM) for continued treatment while providing the Company with data on the long-term safety and efficacy of the product. This would preclude preventing or delaying patients benefiting from continued treatment before product commercialization.
comments powered by